The scientific basis for the current treatment of Parkinson's disease

Annual Review of Medicine

Volumn 55, Issue , 2004, Pages 41-60

  Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Dopamine agonist; Levodopa; Neuroprotection

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ALPHA TOCOPHEROL; AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CASBAR; CATECHOL METHYLTRANSFERASE INHIBITOR; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LEVODOPA METHYL ESTER; LISURIDE; NAXAGOLIDE; PERGOLIDE MESILATE; PRAMIPEXOLE; QUINPIROLE; RASAGILINE; ROPINIROLE; SELEGILINE; TCH 346;

BASAL GANGLION; CELL DEATH; CLINICAL FEATURE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DRUG FORMULATION; DRUG HALF LIFE; HUMAN; MEDICAL RESEARCH; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; UNITED STATES;

ANIMALS; ANTIPARKINSON AGENTS; CELL DEATH; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE;

EID: 1542269162     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.104422     Document Type: Review

References (76)

1. Olanow CW, Watts RL, Koller WC. 2001. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 56(Suppl. 5):1-88
2. Lang AP, Lozano AE. 1998. Parkinson's disease. N. Engl. J. Med. 339:1044-53
3. Forno LS. 1996. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55:259-72
4. Ehringer H, Hornykiewicz O. 1960. Verteilung von Noradrenalin und Dopamin (3-hydroxytyramin) in Gehrin des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klinische Wochenschrift 38:1238-39
5. Hughes AJ, Daniel SE, Kilford L, et al. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55:181-84
6. Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. 1992. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42:1142-46
7. Cotzias GC, Van Woert MH, Schiffer LM. 1967. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276:374-79
8. Obeso JA, Olanow CW, Nutt JG. 2000. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23(Suppl. 2):2-7
9. Olanow CW. 1990. Oxidation reactions in Parkinson's disease. Neurology 40:32-37
10. Goetz C, Koller W, Poewe W, et al. 2002. Management of Parkinson's disease: an evidence-based review. Mov. Disord. 17(Suppl.4):1-166
11. Albin RL, Young AB, Penney JB. 1989. The functional anatomy of basal ganglia disorders. TINS 12:366-75
12. DeLong MR. 1990. Primate models of movement disorders of basal ganglia origin. TINS 13:281-89
13. Gerfen CR. 2000. Molecular effects of dopamine on striatal-projection pathways. TINS 23:64-70 (Suppl.)
14. Bergman H, Wichmann T, Karmon B, et al. 1994 The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 72:507-20
15. Crossman AR, Mitchell IJ, Sambrook MA. 1985. Regional brain uptake of 2-deoxy glucose in MPTP-induced parkinsonism in the Macaque monkey. Neuropharmacology 24:587-591
16. Eidelberg D, Moeller JR, Dhawan V, et al. 1994. Metabolic topography of parkinsonism. J. Cereb. Blood Flow Metab. 14:783-801
17. Bergman H, Wichmann T, DeLong MR. 1990. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-38
18. Brotchie JM, Mitchell IJ, Sambrook MA, et al. 1991. Alleviation of parkinsonism by antagonist of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov. Disord. 6:133-38
19. Laitinen LV, Bergenheim AT, Hariz MI. 1992. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J. Neurosurg. 76:53
20. Limousin P, Krack P, Pollack P, et al. 1998. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 339:1105-11
21. Papa SM, Desimone R, Fioranni M, et al. 1999. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesia. Ann. Neurol. 46:732-38
22. Hutchison WD, et al. 1997. Effects of apomorphine on globus pallidus neurons in Parkinsonian patients. Ann. Neurol. 42:767-75
23. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. 2000. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with current models of the basal ganglia. Ann. Neurol. 47:22-34
24. Olanow CW, Obeso JA, Nutt J, eds. 2000. Basal ganglia, Parkinson's disease, and levodopa therapy. Trends Neurosci. 23(10) (Suppl.)
25. Grace AA. 1991. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24
26. Schultz W. 1998. Predictive reward signal of dopamine neurons. J. Neurosci. 80:1-27.25
27. Olanow CW, Obeso JA. 2000. Preventing levodopa-induced dyskinesia. Ann. Neurol. 47:167-78
28. 3H] spiperone binding. Brain Res. 379:294-99
29. Pearce RK, Banerji T, Jenner P, et al. 1998. De novo administration of ropinirole and bromocriptine induces less dyskinesia than levodopa in MPTP-treated marmoset. Mov. Disord. 13:234-41
30. Jenner P. 2000. Factors influencing the onset and persistence of dyskinesia in MPTP treated primates. Ann. Neurol. 47(4, Suppl. 1):90-99
31. Blanchet PJ, Calon F, Martel JC, et al. 1995. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 272:854-59
32. Morisette M, Goulet M, Soghomonian JJ, et al. 1997. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-dopa therapy. Brain Res. Mol. Brain Res. 49:55-62
33. Rascol O, Brooks DJ, Korczyn AD, et al. 2000. A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med. 342:1484-91
34. Parkinson Study Group. 2000. Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 284:231-38
35. Rinne UK, Bracco F, Chouza C, et al. 1998. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 55(Suppl. 1):23-30
36. Olanow CW, Obeso JA. 2000. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 55(Suppl. 4):72-81
37. Jenner P, Al-Barghouthy G, Smith L, et al. 2002. Initiation of entacapone with L-DOPA further improves antiparkinsonian activity and avoids dyskinesia in the MPTP primate model of Parkinson's disease. Neurology 58(Suppl. 3):374-75
38. Albin RL, Frey KA. 2003. Initial agonist treatment of Parkinson disease. Neurology 60:390-94
39. Parkinson Study Group. 2003. Does levodopa slow or hasten the rate of progression of Parkinson's disease? The results of the Elldopa trial. Neurology 60(Suppl. 1):80-81
40. Agid Y, Olanow CW, Mizuno Y. 2002. Levodopa - why the controversy? Lancet 360:575
41. Lang AE, Lozano AM, Montgomery E, et al. 1997. Posteroventral medial pallidotomy in advanced Parkinson's disease. N. Engl. J. Med. 337:1036-42
42. Vitek JL, Bakay RA, Freeman A, et al. 2003. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann. Neurol. 53:558-69
43. Benabid AL, Pollak P, Gervason C, et al. 1991. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet. 337:403
44. Volkmann J, Sturm V, Weiss P, et al. 1998. Bilateral high frequency stimulation of the internal globus pallidus in advanced Parkinson's disease. Ann. Neurol. 44:953-61
45. The Deep Brain Stimulation for PD Study Group. 2001. Deep brain stimulation of the subthalamic nucleus or globus pallidus pars interna in Parkinson's disease. N. Engl. J. Med. 345:956-63
46. Hadj Tahar A, Gregoire L, Bangassoro E, et al. 2000. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin. Neuropharmacol. 23:195-202
47. Nutt JG, Obeso JA, Stocchi F. 2000. Continuous dopamine receptor stimulation in advanced Parkinson's disease. Trends Neurosci. 23:109-15
48. Stocchi F, Ruggieri S, Vacca L, et al. 2002. Prospective randomized trial of lisuride infusion versus oral levodopa in PD patients. Brain 25:2058-66
49. Olanow CW, Schapira A, Agid Y. 2003. Causes of cell death and prospects for neuroprotection in Parkinson's disease. Ann. Neurol. 53:1-170 (Suppl.)
50. Warner TT, Schapira AH. 2003. Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 53(Suppl. 3):16-23
51. Tanner CM, Ottman R, Goldman SM, et al. 1999. Parkinson disease in twins: an etiologic study. JAMA 281:341-46
52. Olanow CW, Tatton WG. 1999. Etiology and pathogenesis of Parkinson's disease. Ann. Rev. Neurosci. 22:123-44
53. McNaught K St. P, Olanow CW, Halliwell B, et al. 2001. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2:589-94
54. Parkinson's Study Group. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:176-83
55. Olanow CW, Hauser RA, Gauger L, et al. 1995. A longtitudinal double blind controlled study of the affect of deprenyl and levodopa on the progression of the signs and symptoms of Parkinson's disease. Ann. Neurol. 38:771-77
56. Tatton WG, Chalmers-Redman RME, Ju WJH, 2002. Propargylamines induce antiapoptotic new protein synthesis in serum-and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 301:753-64
57. Shults CW, Oakes D, Kieburtz K, et al. 2002. Effect of coenzyme Q10 in early Parkinson's disease: evidence of slowing of the functional decline. Arch. Neurol. 59:1541-50
58. Parkinson Study Group. 2002. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653-61
59. Whone AL, Watts R, Stoessl J, et al. 2003. Slower progression in early Parkinson's disease treated with ropinirole compared with L-DOPA: the REAL-PET study. Ann. Neurol. 54:93-101
60. Schapira AHV, Olanow CW. 2003. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann. Neurol. 53(Suppl. 3):149-59
61. Ahlskog JE. 2003. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 60:381-89
62. Lindvall O, Hagell P. 2001. Cell therapy and transplantation in Parkinson's disease. Clin. Chem. Lab. Med. 39:356-61
63. Lindvall O, Widner H, Rehncrona S, et al. 1992. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol. 31:155-65
64. Freeman TB, Olanow CW, Hauser RA, et al. 1995. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann. Neurol. 38:379-88
65. Kordower JH, Freeman TB, Snow BJ, et al. 1995. Post mortem evidence of dopamine graft survival and striatal reinnervation in a Parkinson's disease patient displaying improved motor function following fetal nigral transplantation. N. Eng. J. Med. 332:1118-24
66. Freed CR, Greene PE, Breeze RE, et al. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344:710-19
67. 66a. Olanow CW, Goetz CG, Kordower JH, et al. 2003. A double blind controlled trial of fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54:403-14
68. Lindvall O. 2003. Stem cells for cell therapy in Parkinson's disease. Pharm. Res. 47:279-87
69. Lee SA, Lumelsky N, Studer L, et al. 2000. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat. Biotechnol. 18: 675-79
70. Bjorklund LM, Sánchez-Pernaute R, Chung S, et al. 2002. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. USA. 99:2344-49
71. Kim J-H, Auerbach JM, Rodriguez-Gomez JA, et al. 2002. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418:50-56
72. Lin L-F, Doherty DH, Lile JD, et al. 1993. A glial cellline-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-32
73. Gash DM, Zhang Z, Ovadia A, et al. 1996. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-55
74. Nutt JG, Burchiel KG, Comella CL, et al. 2003. Randomized double blind trial of glial cell line derived neurotrophic factor (GDNF) in PD. Neurology 14:69-73
75. Gill SS, Patel NK, Hotton GR, et al. 2003. Direct brain infusion of glial cell line derived neurotrophic factor in Parkinson's disease. Nat. Med. 9:589-95
76. Kordower JH, Emborg ME, Bloch J, et al. 2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease Science 290:767-73